For Medical Information requests, please contact:
Phone: 800-520-5568
Fax: 510-595-8183 Email:


Jazz Pharmaceuticals has an unwavering commitment to improving care for patients with serious medical conditions through innovative treatments. Our development pipeline projects currently include clinical development of new product candidates, line extensions for existing products and the generation of additional clinical data for existing products.


Updated 6/15/15

1 Evaluating in children and adolescents who have narcolepsy with cataplexy.
2 Subject to, and dependent upon, the company’s assumption that it will not be required to complete any additional clinical trials prior to the completion of the submission.
3Jazz Pharmaceuticals voluntarily suspended patient enrollment based on the occurrence of hypersensitivity-like reactions following the administration of JZP-416 in some treated patients. The company is in the process of collecting and evaluating the available data and plans to conduct additional research and analysis prior to determining whether to resume the study and determining next steps regarding the development of JZP-416.
VOD = hepatic Veno-Occlusive Disease, aGvHD = acute Graft vs Host Disease, EU = European Union, NDA = New Drug Application